News Chart Genome & Company

Equities

End-of-day quote Korea S.E. Other stock markets 03:30:00 03/06/2024 am IST			5-day change	1st Jan Change
11,840 ^KRW	+29.97%		+46.72%	-5.20%

24/01	Genome & Company Announces Positive Topline Results from Phase 2 Clinical Trial of Combination of GEN-001 and Bavencio®? for the Treatment of Gastric Cancer Poster Presented at ASCO GI	CI
2023	Genome & Company Announces Positive Results from Interim Analysis of Gen-001 Plus Avelumab (Bavencio®?) Phase II Trial	CI

f84de1762.SCvDj-Wy1NK8Mheg2CEaO0qCeOLUXO96NJkg8DZwx6Q.A3n0wKn5muDaAnr_lBF8VxvVFNWzbdpJWaFlmhs19Zw_ZLbAv92QnPlEJw~7c501857d58274612bfb1529d5b02ffc